CFO transition
Petros Pharmaceuticals, Inc. CFO transition: Robert Weinstein to succeed Mitchell Arnold
Petros Pharmaceuticals, Inc. reported in a Form 8-K filed June 18, 2026 that Robert Weinstein will succeed Mitchell Arnold as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective June 18, 2026.
In the filing's words
On June 18, 2026, the board of directors (the “Board”) of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
|---|---|
| Event | Transition |
| Incoming | Robert Weinstein |
| Outgoing | Mitchell Arnold |
| Title in the filing | Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer |
| Effective | June 18, 2026 |
| 8-K filed | June 18, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer, TAO Synergies Inc. |
| SEC CIK | 0001815903 |
Petros Pharmaceuticals, Inc. reported this change in a Form 8-K, Item 5.02, filed June 18, 2026. The filing's own words are quoted above.
Before and after at Petros Pharmaceuticals, Inc.
The adjacent records in the company's seat timeline.
Other records naming Mitchell Arnold
1The outgoing officer on this record, matched by name. Career line.
2026-04-15 · 10-K signature
Mitchell Arnold signed Petros Pharmaceuticals, Inc.'s annual report as Vice President of Finance (Principal Financial and Accounting Officer)
Other records naming Robert Weinstein
1The incoming officer on this record, matched by name. Career line.
6 weeks ago· 2026-09-30DeparturePTPI
Petros Pharmaceuticals, Inc. discloses CFO departure: Robert Weinstein
Same industry, June 2026
8Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
4 months ago· 2026-06-30InterimIMNN
Imunon, Inc. names Josh Blacher interim CFO
4 months ago· 2026-06-30TransitionRANI
Rani Therapeutics Holdings, Inc. CFO transition: Nicholas M. Maestas to succeed Svai Sanford
4 months ago· 2026-06-29InterimCVKD
Cadrenal Therapeutics, Inc. names John P. Sharp interim CFO
5 months ago· 2026-06-18InterimMPLT
MapLight Therapeutics, Inc. names Jonathan Gillis interim CFO
5 months ago· 2026-06-15AppointmentSNSE
Sensei Biotherapeutics, Inc. appoints Brian Stephenson as CFO
5 months ago· 2026-06-12AppointmentOCUL
Ocular Therapeutix, Inc. appoints Jason Robins as CFO
5 months ago· 2026-06-04AppointmentBYSI
BeyondSpring Inc. appoints Na Li as CFO
5 months ago· 2026-06-03InterimCVKD
Cadrenal Therapeutics, Inc. names Quang X. Pham interim CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Robert Weinstein? Send a correction with the primary source.